Predicting outcomes for Crohn's disease using a molecular biomarker: profile trial
Clin Med (Lond)
.
2022 Jul;22(Suppl 4):22-23.
doi: 10.7861/clinmed.22-4-s22.
Authors
Nurulamin Noor
1
,
Biljana Brezina
1
,
Juan De La Revilla Negro
1
,
Francis Dowling
2
,
Simon Bond
2
,
Lynne Whitehead
1
,
Jacinta Lee
3
,
Paul Lyons
3
,
Eoin McKinney
3
,
Kenneth Smith
3
,
James Lee
4
,
Miles Parkes
1
Affiliations
1
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
2
Cambridge Clinical Trials Unit, Cambridge, UK.
3
University of Cambridge School of Clinical Medicine, Cambridge, UK.
4
The Francis Crick Institute, London, UK.
PMID:
36220241
PMCID:
PMC9600841
DOI:
10.7861/clinmed.22-4-s22
No abstract available
Publication types
Clinical Trial
MeSH terms
Biomarkers
Crohn Disease* / diagnosis
Crohn Disease* / drug therapy
Humans
Remission Induction
Substances
Biomarkers